Comparative safety and efficacy of anti-PD-1 monotherapy, chemotherapy alone, and their combination therapy in advanced nasopharyngeal carcinoma: findings from recent advances in landmark trials

Comparative safety and efficacy of anti-PD-1 monotherapy, chemotherapy alone, and their combination therapy in advanced nasopharyngeal carcinoma: findings from recent advances in landmark trials

Abstract Recent phase 1–2 trials reported manageable safety profiles and promising antitumor activities of anti-PD-1 drugs (pembrolizumab, nivolumab, camrelizumab and JS001) with/without chemotherapy in recurrent/metastatic nasopharyngeal carcinoma (RM-NPC), however head-to-head comparison among the...

Full description

Bibliographic Details
Main Authors: Jia-Wei Lv, Jun-Yan Li, Lin-Na Luo, Zi-Xian Wang, Yu-Pei Chen
Format: Article
Language:English
Published: BMJ Publishing Group 2019-06-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Nasopharyngeal carcinoma
Anti-PD-1
Chemotherapy
Combination therapy
Safety profiles
Efficacy
Online Access:http://link.springer.com/article/10.1186/s40425-019-0636-7

Internet

http://link.springer.com/article/10.1186/s40425-019-0636-7

Similar Items